Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04706104
Other study ID # MH2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 10, 2020
Est. completion date March 1, 2021

Study information

Verified date May 2021
Source Ankara City Hospital Bilkent
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In studies, the effects of drugs used for anesthesia and analgesia on QT distance were evaluated in isolation. However, drugs are administered in combination with each other during anesthesia induction. Therefore, drugs interact in terms of positive and undesirable effects. In addition, most of the studies examining anesthesia and QT distance have been conducted in non-cardiac surgery. The target group in this study is the adult patient group who will undergo cardiac surgery. The primary aim of our study is to investigate the effect of two different types of anesthesia induction techniques on QT distance in patients undergoing open-heart surgery. QT evaluation will be performed after endotracheal intubation after anesthesia induction.


Description:

Long QT syndrome (LQTS) is a cardiac conduction disorder characterized by the prolongation and extension of ventricular repolarization. This prolonged repolarization may cause re-entry circuits when sympathetic activity is added and may cause syncope, dizziness, torsades de pointes (TdP), ventricular fibrillation (VF), ventricular tachycardia (VT), or sudden cardiac death (1). LQTS is divided into two groups as congenital and acquired. Drug-induced LQTS is the most common cause of the acquired form. It is known that some drugs used during anesthesia and analgesia management have effects on the QT distance (2). The QT interval is the most commonly used ECG indicator for arrhythmias, representing the action potential duration (3). The prolonged QT interval is a risk marker frequently used in patients with a predisposition to the development of TdP, a type of polymorphic VT or VF variant. Often the QT distance is computed with the corrected QT (QTc) Bazett formula (QTc = QT / √RR). However, non-torsadogenic VT / VF cannot be evaluated with QTc alone, and this has led to the need for new additional biomarkers. A new marker called "Index of cardio-electrophysiological balance (iCEB)" shows the balance between depolarization and repolarization of the action potential. The iCEB calculated by dividing the QT interval by the QRS duration (QT / QRS); In addition to drug-induced long QT and TdP, it is also superior in detecting conduction slowdowns, QT shortening, and associated non-TdP-like VT / VF induced by drugs, especially drugs used in anesthesia management, and is now shown as a potential risk predictor in drug-induced arrhythmias ( 3,4). The secondary aim of our study is to evaluate the effects of drugs used in anesthesia management on QT distance with Bazett and iCEB techniques. The expected benefit from the research is to determine the effects of two different anesthesia induction techniques, in which anesthetic drugs are applied in combination, on the QT prolongation induced by drugs, and to detect QT prolongations in different periods of anesthesia with different QT measurement methods. No study-specific risk is considered. This study was planned prospectively and randomized. If the patients who will undergo open-heart surgery in the cardiovascular surgery operating rooms are evaluated in terms of both anesthesia methods after the preoperative routine evaluation and meet the conditions for participation in the study, the research project will be explained to the patients. If accepted by the patients, verbal and written consent will be obtained and the patients will be included in the study. Anesthesia management and grouping will be determined by the randomization program. A total of 60 adult patients in both groups who will undergo open-heart surgery will be included in the study. Using the randomization program, the patients will be divided into two groups of 30 people. While 2-3 mg/kg propofol and 1-2 mg/kg ketamine will be used for anesthesia induction in the first group, 0.15 mg/kg midazolam and 10-15 mcg/kg fentanyl will be used for anesthesia induction in the other group. Patients with bundle branch block in their preoperative ECG, patients with arrhythmia, allergies specific to known drugs, and patients with electrolyte disorders will not be included in the study. Age, gender, body weight, and height of the patients will be recorded. Patients will be questioned in terms of additional diseases and medicines they use. Preoperative blood sodium, potassium, and calcium values will be evaluated and recorded in terms of electrolyte imbalance. Patients will be taken to the operation room and rested for 1 minute by preoxygenation. Then, 12-lead ECG will be taken to evaluate the QT length with the Bazett formula (QTc = QT / √RR) and the iCEB formula (QT / QRS), and the average arterial pressure, heart rate, oxygen saturation of the patient will be recorded simultaneously. ECG measurements will be analyzed on lead II and lead V5. Afterward, the same parameters will be re-recorded after the completion of anesthesia induction suitable for the groups and the bispectral index value falls below the BIS value of 40. Third and lastly, the same parameters will be recorded 2 minutes after the patients are intubated.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: • Adult patients who will undergo open-heart surgery Exclusion Criteria: - Under the age of 18 years - Bundle branch block in preoperative ECG - Arrhythmia in preoperative ECG - allergies specific to known drugs - Electrolyte disorders

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Ankara City Hospital Ankara

Sponsors (1)

Lead Sponsor Collaborator
Ankara City Hospital Bilkent

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

Fazio G, Vernuccio F, Grutta G, Re GL. Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management. World J Cardiol. 2013 Apr 26;5(4):87-93. doi: 10.4330/wjc.v5.i4.87. — View Citation

Lu HR, Yan GX, Gallacher DJ. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). J Pharmacol Toxicol Methods. 2013 Sep-O — View Citation

Robyns T, Lu HR, Gallacher DJ, Garweg C, Ector J, Willems R, Janssens S, Nuyens D. Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a New Biomarker for the Identification of Patients at Increased Arrhythmic Risk. Ann Noninvasive Electr — View Citation

Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary QT distance- baseline- pre-induction of anesthesia 12-lead ECG will be taken to evaluate the QT distance with the Bazett formula (QTc = QT / vRR) and the iCEB formula (QT / QRS) Pre-induction of anesthesia, an average of 5 minutes
Primary QT distance- post-induction of anesthesia 12-lead ECG will be taken to evaluate the QT distance with the Bazett formula (QTc = QT / vRR) and the iCEB formula (QT / QRS) After the completion of anesthesia induction suitable for the groups and the bispectral index value falls below the BIS value of 40, an average of 5 minutes
Primary QT distance- after intubation 12-lead ECG will be taken to evaluate the QT distance with the Bazett formula (QTc = QT / vRR) and the iCEB formula (QT / QRS) 2 minutes after the patients are intubated
See also
  Status Clinical Trial Phase
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4
Completed NCT01648205 - Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Phase 2
Recruiting NCT06087367 - Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
Recruiting NCT04675788 - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening Phase 4
Completed NCT05759962 - Phase 1 Study of LQT-1213 in Healthy Adults Phase 1
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated NCT02439645 - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Recruiting NCT04336644 - Continuous Versus Intermittent cARdiac Electrical moNitorinG N/A
Recruiting NCT02814981 - Hydroxyzine and Risk of Prolongation of QT Interval N/A
Completed NCT02425189 - The Canadian National Long QT Syndrome Registry
Completed NCT02876380 - Prospective Identification of Long QT Syndrome in Fetal Life
Completed NCT00399412 - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients N/A
Completed NCT02513940 - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Phase 4
Completed NCT02441829 - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Phase 1
Completed NCT03182777 - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies N/A
Completed NCT01849003 - Study of the Effect of GS-6615 in Subjects With LQT-3 Phase 1
Completed NCT00316459 - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects Phase 1
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Recruiting NCT05348564 - Comparing Direct vs Indirect Methods for Cascade Screening N/A